Copyright
©The Author(s) 2021.
World J Exp Med. Mar 20, 2021; 11(2): 17-29
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
Table 3 Administration schedule
| Rounds | Route | WJ-MSC |
| Round 1 | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 2 (2nd week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 3 (4th week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 4 (6th week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL |
- Citation: Kabataş S, Civelek E, Kaplan N, Savrunlu EC, Sezen GB, Chasan M, Can H, Genç A, Akyuva Y, Boyalı O, Diren F, Karaoz E. Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World J Exp Med 2021; 11(2): 17-29
- URL: https://www.wjgnet.com/2220-315x/full/v11/i2/17.htm
- DOI: https://dx.doi.org/10.5493/wjem.v11.i2.17